149 related articles for article (PubMed ID: 23723122)
1. Efficacy of the specific endothelin a receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study.
Haque SU; Dashwood MR; Heetun M; Shiwen X; Farooqui N; Ramesh B; Welch H; Savage FJ; Ogunbiyi O; Abraham DJ; Loizidou M
Mol Cancer Ther; 2013 Aug; 12(8):1556-67. PubMed ID: 23723122
[TBL] [Abstract][Full Text] [Related]
2. Altered endothelin receptor subtypes in colorectal cancer.
Hoosein MM; Dashwood MR; Dawas K; Ali HM; Grant K; Savage F; Taylor I; Loizidou M
Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):775-82. PubMed ID: 17700263
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of zibotentan with cisplatinum and paclitaxel is an effective regimen for epithelial ovarian cancer.
Rosanò L; Cianfrocca R; Spinella F; Di Castro V; Natali PG; Bagnato A
Can J Physiol Pharmacol; 2010 Jun; 88(6):676-81. PubMed ID: 20628434
[TBL] [Abstract][Full Text] [Related]
4. Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054.
Growcott JW
Anticancer Drugs; 2009 Feb; 20(2):83-8. PubMed ID: 19065106
[TBL] [Abstract][Full Text] [Related]
5. Targeting endothelin receptor type A in human cervical carcinoma cells.
Cirilli A; Simeone P; Muller A; Bagnato A; Venuti A
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S72-5. PubMed ID: 15838364
[TBL] [Abstract][Full Text] [Related]
6. Increased endothelin-1 in colorectal cancer and reduction of tumour growth by ET(A) receptor antagonism.
Asham E; Shankar A; Loizidou M; Fredericks S; Miller K; Boulos PB; Burnstock G; Taylor I
Br J Cancer; 2001 Nov; 85(11):1759-63. PubMed ID: 11742499
[TBL] [Abstract][Full Text] [Related]
7. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
Rosanò L; Di Castro V; Spinella F; Nicotra MR; Natali PG; Bagnato A
Mol Cancer Ther; 2007 Jul; 6(7):2003-11. PubMed ID: 17620430
[TBL] [Abstract][Full Text] [Related]
8. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.
Warren R; Liu G
Expert Opin Investig Drugs; 2008 Aug; 17(8):1237-45. PubMed ID: 18616419
[TBL] [Abstract][Full Text] [Related]
9. ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole.
Smollich M; Götte M; Fischgräbe J; Macedo LF; Brodie A; Chen S; Radke I; Kiesel L; Wülfing P
Breast Cancer Res Treat; 2010 Sep; 123(2):345-57. PubMed ID: 19943105
[TBL] [Abstract][Full Text] [Related]
10. Effect of endothelin receptor antagonists on ventricular susceptibility in postinfarcted rats.
Lee TM; Chen CC; Lin MS; Chang NC
Am J Physiol Heart Circ Physiol; 2008 Apr; 294(4):H1871-9. PubMed ID: 18281380
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-1 promotes osteosarcoma cell invasion and survival against cisplatin-induced apoptosis.
Zhao Y; Liao Q; Zhu Y; Long H
Clin Orthop Relat Res; 2011 Nov; 469(11):3190-9. PubMed ID: 21656314
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of zibotentan in colorectal cancer--letter.
Vlachostergios PJ
Mol Cancer Ther; 2014 Jun; 13(6):1673. PubMed ID: 24837079
[No Abstract] [Full Text] [Related]
13. Efficacy of zibotentan in colorectal cancer--response.
Haque SU; Welch H; Dashwood M; Ramesh B; Loizidou M
Mol Cancer Ther; 2014 Jun; 13(6):1674. PubMed ID: 24837078
[No Abstract] [Full Text] [Related]
14. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.
Morris CD; Rose A; Curwen J; Hughes AM; Wilson DJ; Webb DJ
Br J Cancer; 2005 Jun; 92(12):2148-52. PubMed ID: 15956965
[TBL] [Abstract][Full Text] [Related]
15. Endothelin-1 stimulates colon cancer adjacent fibroblasts.
Knowles JP; Shi-Wen X; Haque SU; Bhalla A; Dashwood MR; Yang S; Taylor I; Winslet MC; Abraham DJ; Loizidou M
Int J Cancer; 2012 Mar; 130(6):1264-72. PubMed ID: 21445967
[TBL] [Abstract][Full Text] [Related]
16. Endothelin ET(A) but not ET(B) receptors mediate contraction of common bile duct.
Huang SC
Regul Pept; 2003 May; 113(1-3):131-8. PubMed ID: 12686472
[TBL] [Abstract][Full Text] [Related]
17. Selective ETAR antagonist atrasentan inhibits hypoxia-induced breast cancer cell invasion.
Smollich M; Götte M; Kersting C; Fischgräbe J; Kiesel L; Wülfing P
Breast Cancer Res Treat; 2008 Mar; 108(2):175-82. PubMed ID: 17468950
[TBL] [Abstract][Full Text] [Related]
18. Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor.
Montgomery JP; Patterson PH
BMC Cancer; 2008 Nov; 8():354. PubMed ID: 19040731
[TBL] [Abstract][Full Text] [Related]
19. Endothelin-A receptor in gastric cancer and enhanced antitumor activity of trastuzumab in combination with the endothelin-A receptor antagonist ZD4054.
Shen W; Xi H; Li C; Bian S; Cheng H; Cui J; Wang N; Wei B; Huang X; Chen L
Ann N Y Acad Sci; 2019 Jul; 1448(1):30-41. PubMed ID: 30937921
[TBL] [Abstract][Full Text] [Related]
20. Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers.
Clarkson-Jones JA; Kenyon AS; Kemp J; Lenz EM; Oliver SD; Swaisland H
Xenobiotica; 2012 Apr; 42(4):363-71. PubMed ID: 22014279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
